July 5, 2023
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of experts will discuss how psychedelics
June 21, 2023
With a growing belief that research around the potential of psychedelics is finally making key policymakers within the European Parliament
June 20, 2023
Traditional psychedelic medicines work by binding to receptors that detect serotonin, antagonising the 5-HT2a receptor specifically. Ketamine, however, works by
May 24, 2023
PSYCH Symposium: London 2023 is returning on 6 July at the iconic British Museum to explore the latest challenges and
May 17, 2023
Psilocybin therapy for treatment-resistant depression is currently in Phase III clinical trials, and may be approved by the FDA as
May 10, 2023
When MAPS completed its Phase IIIa trials with MDMA in the treatment of PTSD, the subsequent data release grabbed headlines
May 2, 2023
A debate on ‘Psilocybin Access Rights’ is expected to be heard in the House of Commons later this month. The
April 20, 2023
After a sold-out conference in 2022, PSYCH Symposium is returning to bring together leading investors, regulators, scientists and industry leaders
April 19, 2023
On 19 April 1943, eighty years ago today, Albert Hofmann intentionally consumed LSD, marking the first recorded experience with the
April 12, 2023
We have witnessed an exponential increase in the number of companies developing proprietary analogues of psychedelic compounds such as psilocybin,
April 5, 2023
Contributed article by Matt Zorn, Partner at Yetter Coleman, for The Psychedelics As Medicine Report: Fourth Edition. The patent portfolio
March 29, 2023
Regulatory reform to decriminalise the use of psilocybin is taking place in a dozen states across the US, and is
